Ubi Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services.

Employees

Sector

Pharmaceuticals

More about the company

End-of-day quote Taipei Exchange 06/05/2024			5-day change	1st Jan Change
14.25 ^TWD	+1.79%		-.--%	-

13/08	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
27/04	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	168.32Cr 5.33Cr 4.59Cr 4.32Cr 3.94Cr 7.37Cr 504.53Cr 7.39Cr 51Cr 20Cr 258.37Cr 20Cr 20Cr 822.98Cr	P/E 2024	-9.63x	P/E 2025	-5.68x
Enterprise Value	197.21Cr 6.25Cr 5.38Cr 5.06Cr 4.62Cr 8.63Cr 591.12Cr 8.66Cr 60Cr 23Cr 302.71Cr 23Cr 23Cr 964.22Cr	EV / Sales 2024	3.58x	EV / Sales 2025	3.83x
Free-Float	27.79%	Yield 2024 *	-	Yield 2025	-

13/08	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
27/04	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/25/12	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/24/13	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
18/24/18	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/23/11	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
21/23/21	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
15/22/15	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
29/22/29	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
29/22/29	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/21/16	Medigen Vaccine Biologics : Taiwan rejects COVID vaccine candidate, president to get domestic shot	RE
16/21/16	Medigen Vaccine Biologics : Taiwan denies approval for UBI's COVID-19 vaccine candidate	RE

3 years	10	38.5
5 years	10	136.66
10 years	8.34	288.72

UBI Pharma Inc. Share Price

Stocks

6562

TW0006562002

Pharmaceuticals

Valuation : UBI Pharma Inc.

Latest news : UBI Pharma Inc.

Quotes and Performance

Price Extremes

Managers and Directors : UBI Pharma Inc.

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Jung Kuang Yang CEO	Chief Executive Officer	-	-
Meng Han Hsu DFI	Director of Finance/CFO	-	11/04/2016
Ying Yun Fan ADM	Chief Administrative Officer	-	01/03/2015

Director	Title	Age	Since
Ying Yun Fan BRD	Director/Board Member	-	30/06/2020
Yan Ning Kuo BRD	Director/Board Member	-	30/06/2020
Yao Hui Wei BRD	Director/Board Member	-	30/06/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
UBI PHARMA INC.	+1.79%	-.--%	-.--%	-56.42%	5.32Cr
ELI LILLY AND COMPANY	-0.88%	-0.64%	+58.05%	+100.51%	1,02400Cr
JOHNSON & JOHNSON	-1.15%	+3.53%	+54.25%	+71.99%	66TCr
ABBVIE INC.	-1.44%	+0.02%	+20.65%	+72.22%	45TCr
ROCHE HOLDING AG	-0.95%	-1.42%	+28.96%	+40.10%	35TCr
NOVARTIS AG	-3.18%	+1.39%	+20.66%	+43.86%	30TCr
ASTRAZENECA PLC	+0.30%	+0.60%	-0.40%	+13.54%	25TCr
AMGEN INC.	-1.55%	+1.71%	+54.15%	+71.87%	24TCr
NOVO NORDISK A/S	+0.02%	+1.17%	-14.59%	-54.96%	21TCr
GILEAD SCIENCES, INC.	-0.15%	+3.18%	+31.24%	+104.21%	19TCr
Average	-0.72%	+1.61%	+25.30%	+40.69%	36.78TCr
Weighted average by Cap.	-1.07%	+0.64%	+37.20%	+65.12%

	2024	2025
Net sales	54Cr 1.71Cr 1.47Cr 1.38Cr 1.26Cr 2.36Cr 161.51Cr 2.37Cr 16Cr 6.33Cr 83Cr 6.41Cr 6.27Cr 263.45Cr	51Cr 1.63Cr 1.4Cr 1.32Cr 1.2Cr 2.25Cr 154.2Cr 2.26Cr 16Cr 6.04Cr 79Cr 6.12Cr 5.99Cr 251.52Cr
Net income	-17Cr -55.31L -47.57L -44.74L -40.84L -76.38L -52Cr -76.63L -5.3Cr -2.05Cr -27Cr -2.08Cr -2.03Cr -85Cr	-30Cr -93.9L -80.76L -75.95L -69.33L -1.3Cr -89Cr -1.3Cr -9.01Cr -3.48Cr -45Cr -3.53Cr -3.45Cr -144.86Cr
Net Debt	25Cr 78.08L 67.15L 63.15L 57.65L 1.08Cr 74Cr 1.08Cr 7.49Cr 2.89Cr 38Cr 2.93Cr 2.87Cr 120.45Cr	29Cr 91.56L 78.74L 74.06L 67.61L 1.26Cr 87Cr 1.27Cr 8.78Cr 3.39Cr 44Cr 3.44Cr 3.36Cr 141.25Cr